Establishment Labs announces that Pratip Dastidar has joined the company as Head of Global Operations



SANTA BARBARA, Calif .– (BUSINESS WIRE) – Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the aesthetic and breast reconstruction market, today announced the appointment of Pratip Dastidar leading global operations.

Mr. Dastidar will join the leadership team at Establishment Labs with responsibility for operational transformation and scaling of global operations; he will also lead the company’s digital transformation initiatives. Mr. Dastidar joins Establishment Labs after serving as Chief Transformation Officer from 2018 to 2020. He was previously responsible for process innovation at Salesforce and held leadership positions at Hewlett Packard, Amazon, Applied Materials, WABCO and other. Mr. Dastidar’s experience spans industry, technology and service sectors as well as multiple regions of the world. He was also previously a consultant at McKinsey & Company and holds a PhD. in mechanical engineering.

“With incredible opportunities ahead, we are taking steps to align the operational structure of the company with our growth strategy and product development efforts. Scaling up global operations and integrating our global business channels will allow us to better meet the growing needs of our partners and patients, ”said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs . “Pratip’s experience in transforming and scaling business processes will be invaluable as we launch new technologies and enter important new markets.”

Commenting on his new role, Mr. Dastidar added, “Establishment Labs are an industry disruptor and I look forward to contributing to their mission to improve the health of women in aesthetic medicine. As we grow this business globally, we can increase operational efficiency through the combination of manufacturing, supply chain and digital technology. ”

Along with today’s announcement on the appointment of Mr. Dastidar, Establishment Labs also announced that Salvador Dada, who has been on sick leave since March 19, 2021, will return to the company in the near future as as Special Projects Manager, the first of which will oversee the company’s expansion into new manufacturing facilities and research and development laboratories in the Coyol Free Zone in Costa Rica. This initiative will support the future growth of Establishment Labs in its current and new markets, including China and the United States.

About Establishment Labs

Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a global medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, by designing, developing, manufacturing and marketing an innovative portfolio of breast implants filled with silicone gel, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform. Motiva Implants® are produced at our two manufacturing sites in accordance with ISO13485: 2016, FDA 21 CFR 820 as part of the MDSAP program, and are currently commercially available in over 80 countries through exclusive distributors or the company’s direct sales force. In March 2018, Establishment Labs received FDA approval for an Investigational Device Exemption (IDE) and launched the Motiva Implant® clinical trial in the United States in April 2018. In addition to Motiva Implants®, the product portfolio and Establishment Labs technology includes the Divina® 3D simulation system and other products and services. Please visit our website for more information at www.establishmentlabs.com.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can find most of these statements (but not all) by searching for words such as “approximate”, “believe”, “expect”, “anticipate”, “estimate”, “intend”, “plan” “,” Would, “” May “or other similar expressions in this press release, and include statements relating to our expected growth, scale-up, product development, future markets, new facility and digital transformation. Any statement that refers to projections of our future financial or operating performance, anticipated trends in our business, our objectives, strategies, priorities and plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the performance of the company are forward-looking statements. We claim the safe harbor protection contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements made in this report, or that we may make orally or in writing from time to time, are expressions our beliefs and expectations based on information currently available at the time such statements are made. These statements are based on assumptions and actual results will be affected by known and unknown risks, trends, uncertainties and factors that are beyond our control. While we believe our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. Therefore, our actual future results may differ from our expectations and these differences may be material. Factors that could cause or contribute to these differences include, among others, the risks and uncertainties discussed in the company’s annual report on Form 10-K filed on March 15, 2021, the quarterly reports on Form 10-Q and d ” other filings made by the company with the Securities and Exchange Commission. The risks included in these documents are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all of these risk factors, nor to assess the impact of all of these risk factors on our business or the extent to which any factor or a combination of factors may cause actual results to differ materially from those contained in forward-looking statements. We assume no obligation to update any forward-looking statements. Therefore, investors should exercise caution in relying on prior forward-looking statements, which are based on results and trends known at the time they are made, to anticipate future results or trends.



Source link

Previous Antiques Road Trip's Anita Manning Breaks Records with Staggering Profits on Buddha Statue
Next Hollywood legend Gina Lollobrigida 'con art and antiques' worth € 300,000